ENZEEVU

Product NDC
61314-504
11-digit product format
613140504
Labeler code
61314
Product ID
61314-504_6f1d28a8-1c10-40d2-83f0-6a528f807b92
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
aflibercept
Dosage form
INJECTION, SOLUTION
Route
INTRAVITREAL
Labeler
Sandoz Inc
Application
BLA761382
Marketing category
BLA
Marketing start
2026-10-26
Substance
AFLIBERCEPT
Active strength
2 mg/.05mL
Pharmacologic classes
Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded packagepackage61314-50461314-504-94DDiscontinued by firm2026-11-19

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product
Yes
Brand name base
ENZEEVU
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
AFLIBERCEPT2 mg/.05mL

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
15C2VL427DInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
2754974Internal RxNorm lookup
2754981Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
6f1d28a8-1c10-40d2-83f0-6a528f807b92Available on FDA.report

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ENZEEVUAFLIBERCEPTSandoz Inc6f1d28a8-1c10-40d2-83f0-6a528f807b922026-04-24Warnings, Adverse reactionsExact identifier
application number: BLA761382
ndc (product): 61314-504

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761382Enzeevuaflibercept-abzv351(k) InterchangeableRx2026-10-01

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
61314-504-63613140504631 SYRINGE, GLASS in 1 CARTON (61314-504-63) / .05 mL in 1 SYRINGE, GLASS2026-10-26NoNoCurrent